APP下载

米托蒽醌单独及其联合美罗华治疗恶性淋巴瘤的疗效探讨

2016-05-14聂艳霞张志彪任小晶刘小洁段菲菲

中外医疗 2016年5期
关键词:疗效

聂艳霞 张志彪 任小晶 刘小洁 段菲菲

[摘要] 目的 探讨米托蒽醌单独及其联合美罗华治疗非霍奇金恶性淋巴瘤(NHL)的疗效。 方法 随机选取该院2007年10月—2013年10月收治的40例非霍奇金恶性淋巴瘤患者,抽签随机分为对照组和观察组,每组各20例。对照组患者给予含米托蒽醌化疗方案治疗,观察组采用含米托蒽醌化疗方案联合美罗华治疗,比较两组治疗效果。 结果 观察组治疗有效率95.0%较对照组70.0%明显较高,差异有统计学意义(P<0.05),观察组2年、5年的无复发生存率(RFS)和总生存率(OS)均高于对照组;观察组不良反应率16.36%较对照组32.73%显著较低,差异有统计学意义(P<0.05)。 结论 含米托蒽醌化疗方案联合美罗华能有效治疗非霍奇金恶性淋巴瘤,提高无复发生存率和总生存率,且未引起其他不良反应症状,耐受性较好,临床综合效果较为显著。

[关键词] 恶性淋巴瘤;米托蒽醌;美罗华;疗效

[中图分类号] R5 [文献标识码] A [文章编号] 1674-0742(2016)02(b)-0047-03

[Abstract] Objective To observe the effect of mitoxantrone alone and it combined with rituximab in the treatment of non-Hodgkins lymphoma (NHL). Methods 40 cases with NHL admitted in our hospital from October 2007 to October 2013 were selected and randomly divided into control group and observation group, 20 cases in each group by drawing lots. The control group were treated by mitoxantrone chemotherapy regimen, the observation group were treated by mitoxantrone chemotherapy regimen combined with rituximab. The therapeutic effects of the two groups were compared. Results The effective rate in the observation group was significantly higher than that in the control group (95.0% vs 70.0%) with statistically significant difference (P<0.05). The 2-year and 5-year recurrence-free survival (RFS) was higher in the observation group than that in the control group. The 2-year and 5-year overall survival (OS) was higher in the observation group than that in the control group. The incidence of adverse reactions was much lower in the observation group than that in the control group (16.36% vs 32.73%) with statistically significant difference (P<0.05). Conclusion Mitoxantrone chemotherapy regimen combined with rituximab is effective in the treatment of NHL, which can increase the RFS and OS with good tolerance and significant clinical effect but has no other adverse reactions.

[Key words] Malignant lymphoma; Mitoxantrone; Rituximab; Curative effect

淋巴瘤是原发与淋巴结或淋巴组织的恶性肿瘤,多发于31~40岁人群,临床以无痛性、进行性淋巴结肿大为主要表现[1]。非霍奇金恶性淋巴瘤是具有相当异质性的一大类肿瘤,可侵犯全身任何组织和器官,患者临床多表现为全身无力、食欲不振、疼痛等症状,并伴有相关组织部位功能衰退[2]。目前治疗非霍奇金恶性淋巴瘤药物较多,且用药方法不一,为选择较为有效的治疗药物,该院于2007年10月—2014年10月对收治的40例非霍奇金恶性淋巴瘤患者分组分别采用米托蒽醌单独及其联合美罗华治疗,观察两组临床治疗效果,现报道如下。

1 资料与方法

1.1 一般资料

研究对象为整群选取该院2007年10月—2014年10月收治的非霍奇金恶性淋巴瘤患者,均经临床病理确诊为侵袭性B-NHL、CD20(+)。抽签随机分为对照组和观察组各20例。对照组男13例,女7例,年龄29~74岁,平均年龄(49.7±5.4)岁,其中弥漫大B细胞淋巴瘤14例,胃粘膜相关型淋巴型淋巴瘤4例,滤泡细胞淋巴瘤2例;……

登录APP查看全文

猜你喜欢

疗效
止眩汤改良方治疗痰瘀阻窍型眩晕的临床疗效观察
冷喷联合湿敷甘芩液治疗日晒疮的短期疗效观察
中西医结合治疗慢性盆腔炎的疗效观察
回药失荅剌知丸治疗中风后痴呆的疗效观察
蒙医药治疗无症状型心肌缺血疗效观察
中西医结合治疗乳痈的疗效观察
脐灸治疗脑卒中后便秘的疗效
旋转DSA指导下介入治疗脑动脉瘤的疗效观察
破裂腹主动脉瘤的腔内修复术与开放手术疗效比较
止嗽散联合阿斯美治疗感染后咳嗽疗效观察